TRCT
MXCT icon

Tower Research Capital (TRC)’s MaxCyte MXCT Stock Holding History

Tower Research Capital (TRC)’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66.3K Buy
53,931
+27,994
+108% +$27.9K ﹤0.01% 2524
2026
Q1 		$18.2K Buy
25,937
+18,628
+255% +$17.4K ﹤0.01% 3543
2025
Q4 		$11.3K Buy
7,309
+715
+11% +$1.14K ﹤0.01% 3613
2025
Q3 		$10.4K Sell
6,594
-5,705
-46% -$9.91K ﹤0.01% 3981
2025
Q2 		$26.8K Buy
12,299
+7,474
+155% +$18.1K ﹤0.01% 3490
2025
Q1 		$13.2K Sell
4,825
-2,739
-36% -$10.8K ﹤0.01% 3397
2024
Q4 		$31.5K Buy
7,564
+4,173
+123% +$15.8K ﹤0.01% 2874
2024
Q3 		$13.2K Sell
3,391
-9,686
-74% -$40.8K ﹤0.01% 3536
2024
Q2 		$51.3K Buy
13,077
+11,335
+651% +$48.8K ﹤0.01% 3081
2024
Q1 		$7.3K Sell
1,742
-38,252
-96% -$180K ﹤0.01% 4228
2023
Q4 		$188K Buy
39,994
+36,990
+1,231% +$144K ﹤0.01% 2158
2023
Q3 		$9.37K Sell
3,004
-4,153
-58% -$16.7K ﹤0.01% 4227
2023
Q2 		$32.9K Buy
7,157
+49
+0.7% +$225 ﹤0.01% 2944
2023
Q1 		$35K Buy
7,108
+4,144
+140% +$20.4K ﹤0.01% 2842
2022
Q4 		$16K Sell
2,964
-17,712
-86% -$109K ﹤0.01% 3360
2022
Q3 		$134K Buy
20,676
+15,573
+305% +$86.9K ﹤0.01% 2289
2022
Q2 		$24K Buy
5,103
+3,689
+261% +$18.2K ﹤0.01% 3610
2022
Q1 		$9K Sell
1,414
-1,884
-57% -$12.9K ﹤0.01% 4470
2021
Q4 		$33K Sell
3,298
-4,918
-60% -$52.8K ﹤0.01% 3134
2021
Q3 		$100K Buy
+8,216
New +$124K ﹤0.01% 2400

Other funds holding MXCT

CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BFM
Brooklands Fund Management London, United Kingdom $128M AUM
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Tower Research Capital (TRC)'s MXCT Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its MaxCyte (MXCT) stake by 108% in Q2 2026, buying an estimated $27.9K and bringing the position to 53,931 shares worth $66.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2524.

Tower Research Capital (TRC) first reported a position in MXCT in Q3 2021 and has held it in 20 quarters since. The position peaked at $188K in Q4 2023. 122 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

  • Tower Research Capital (TRC) held 53,931 shares of MaxCyte worth $66.3K as of Q2 2026.
  • Tower Research Capital (TRC) bought 27,994 MaxCyte shares in Q2 2026, an estimated $27.9K.
  • MaxCyte made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2524 holding.
  • Tower Research Capital (TRC) first reported a position in MaxCyte in Q3 2021 and has held it in 20 quarters since.
  • Tower Research Capital (TRC)'s MaxCyte position peaked at $188K in Q4 2023.
  • 122 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.